Hepa1-6 Syngeneic Model Overview
The Hepa1-6 syngeneic model is a murine hepatocellular carcinoma (HCC) system derived from C57BL/6 mice. It represents one of the most frequently used preclinical models for studying liver cancer biology, immunotherapy, and combination therapeutic strategies. Hepa1-6 tumors exhibit epithelial morphology, moderate aggressiveness, and strong vascularization, recapitulating many histopathological features of human hepatocellular carcinoma.
When implanted subcutaneously or orthotopically into the liver, Hepa1-6 cells form reproducible tumors that are well-suited for evaluating immune checkpoint inhibitors, cytokine therapies, and anti-angiogenic agents. The model’s immunocompetent host background enables detailed investigation of tumor–immune interactions, macrophage polarization, and the development of resistance mechanisms in liver cancer. Owing to its consistent growth and immune responsiveness, Hepa1-6 has become a cornerstone system in preclinical hepatocellular carcinoma research.
Request a Custom Quote for Hepa1-6 Syngeneic ModelBiological and Molecular Characteristics
The Hepa1-6 cell line was established from a spontaneous hepatoma in a C57BL/6 mouse and retains hepatocyte-like characteristics, including polygonal morphology and production of hepatic enzymes. It expresses typical markers of hepatocellular carcinoma such as alpha-fetoprotein (AFP) and albumin, confirming its hepatic origin. Hepa1-6 tumors demonstrate active proliferation and angiogenesis, supported by expression of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and matrix metalloproteinases.
The tumor microenvironment of Hepa1-6 is characterized by a mixed immune infiltrate that includes macrophages, dendritic cells, and T lymphocytes. This balanced immune composition allows for robust analysis of immunotherapy efficacy, immune checkpoint dynamics, and cytokine signaling pathways. The model’s reproducible growth and defined immune environment make it particularly suitable for evaluating the immune modulation and anti-tumor effects of novel biologic or small molecule agents.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Spontaneous hepatocellular carcinoma (mouse) |
| Histological type | Moderately differentiated carcinoma |
| Inoculation route | Subcutaneous or orthotopic (liver) |
| Tumor take rate | >95% |
| Doubling time | Approximately 4–5 days in vivo |
| Metastatic potential | Low to moderate; dependent on implantation route |
| Immunophenotype | Mixed lymphocyte and macrophage infiltration |
| Common applications | Immunotherapy, anti-angiogenic therapy, cytokine studies, HCC drug testing |
In Vivo Model Development and Tumorigenicity
The Hepa1-6 model can be established by either subcutaneous or orthotopic inoculation of viable tumor cells into immunocompetent C57BL/6 mice. Subcutaneous implantation produces rapidly growing, measurable tumors within one week and is often used for immunotherapy screening. Orthotopic implantation into the liver generates a more physiologically relevant environment that recapitulates hepatic blood flow, vascularization, and immune cell distribution, enabling more accurate assessment of liver-targeted therapeutic efficacy.
Hepa1-6 tumors exhibit reproducible kinetics, with minimal spontaneous metastasis unless implanted orthotopically, where local invasion and occasional pulmonary or lymphatic spread can occur. This model’s predictable growth and consistent immune response make it a valuable system for longitudinal studies assessing tumor regression, immune activation, and hepatic toxicity under different therapeutic regimens.
Request a Custom Quote for Hepa1-6 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological evaluation of Hepa1-6 tumors shows polygonal hepatocyte-like cells arranged in trabecular and solid patterns, resembling human hepatocellular carcinoma. The tumors demonstrate moderate mitotic activity, clear cytoplasm, and central areas of necrosis surrounded by viable tissue. The stroma contains fibroblasts, sinusoidal endothelial cells, and infiltrating immune populations, reflecting the highly vascularized and immune-active nature of liver tumors.
Immunohistochemical staining confirms strong expression of hepatocellular markers such as alpha-fetoprotein and cytokeratin-8/18. Ki-67 staining indicates high proliferative activity, while CD31 highlights extensive vascular networks. CD3 and CD8 staining identify T-cell infiltration within the parenchyma, and F4/80 staining confirms macrophage presence. PD-L1 expression is moderate at baseline and increases following exposure to interferon signaling or immune checkpoint inhibition. These histological and immunological features make Hepa1-6 a robust model for translational liver cancer research.
Preclinical Applications and Drug Response
The Hepa1-6 syngeneic model has become a standard system for evaluating therapeutic approaches in hepatocellular carcinoma. It is widely used to test immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies, both as monotherapy and in combination with cytokine or anti-angiogenic agents. The model demonstrates partial responsiveness to checkpoint blockade, which can be enhanced through co-administration of interferons, IL-12, or VEGF inhibitors.
Hepa1-6 tumors have also been employed to study the impact of oncolytic viruses, cancer vaccines, and adoptive T-cell therapies in an immune-competent hepatic environment. Due to its reproducibility and strong vascular component, it serves as an effective system for testing anti-angiogenic drugs such as sorafenib and lenvatinib. The combination of controlled tumor growth, measurable immune activity, and liver-specific pathology makes Hepa1-6 one of the most relevant preclinical models for immuno-oncology and drug development in hepatocellular carcinoma.
Request This Model
To request the Hepa1-6 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for Hepa1-6 Syngeneic Model